A Study on TLC590 for Managing Postsurgical Pain
NCT06574269
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This Phase 2 open-label trial investigates the pharmacokinetics (PK), pharmacodynamics, and safety profile of TLC590 across various surgical procedures. Researchers aim to determine the maximum tolerated dose (MTD) of TLC590 via Safety Monitoring Committee (SMC). The study evaluates TLC590 in bunionectomy, laparoscopy-assisted open ventral hernia repair, breast augmentation, abdominoplasty, and total knee arthroplasty models. Additionally, it determines the relative bioavailability of TLC590 to ropivacaine injection.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Postsurgical Pain Management
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- TLC Biopharmaceuticals, Inc.
- Last updated on ClinicalTrials.gov
- December 2, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 2
- First Surgical Hospital · Bellaire, TX
- Memorial Hermann Village · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.